Related Experiment Video

Updated: May 4, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

2.4K

Treatment of Chagas cardiomyopathy

Fernando A Botoni1, Antonio Luiz P Ribeiro2, Carolina Coimbra Marinho3

  • 1Postgraduate Course of Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, 30130 100 Belo Horizonte, MG, Brazil ; Hospital das Clínicas, Universidade Federal de Minas Gerais, 30130 100 Belo Horizonte, MG, Brazil ; Fundação Hospitalar do Estado de Minas Gerais, 30150 260 Belo Horizonte, MG, Brazil.

Biomed Research International
|December 19, 2013
PubMed

Insights

Chagas

Area of Science:

  • Tropical Medicine
  • Cardiology
  • Infectious Diseases

Background:

  • Chagas' disease (ChD), caused by Trypanosoma cruzi, is a neglected tropical disease prevalent in South America.
  • It poses a growing global health challenge due to endemic cases and migration.
  • The pathophysiology of chronic chagas cardiomyopathy (CCC) remains poorly understood.

Purpose of the Study:

  • To review the treatment of Chagas cardiomyopathy (CCC).
  • To highlight the unique aspects of CCC treatment.
  • To address the therapeutic gap in managing this condition.

Main Methods:

  • Literature review focusing on Chagas' disease and cardiomyopathy.
  • Analysis of existing therapeutic strategies for CCC.
  • Emphasis on peculiarities in CCC management.

Main Results:

  • Current CCC treatment often adapts approaches from other cardiomyopathies.
  • Understanding CCC pathophysiology is crucial for targeted therapies.
  • Specific treatment considerations for Chagas cardiomyopathy are identified.

Conclusions:

  • Effective management of Chagas' disease requires specialized approaches.
  • Further research into CCC pathophysiology is essential for improved treatment outcomes.
  • This review aims to guide clinicians in treating Chagas cardiomyopathy.

More Related Videos

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response07:59

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response

Published on: May 31, 2024

2.1K
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

14.4K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
481
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952